Auxier Asset Management lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 4.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 24,075 shares of the medical instruments supplier’s stock after selling 1,050 shares during the period. Becton Dickinson and makes up about 1.2% of Auxier Asset Management’s holdings, making the stock its 28th biggest position. Auxier Asset Management’s holdings in Becton Dickinson and were worth $5,767,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in BDX. American Century Companies Inc. boosted its stake in shares of Becton Dickinson and by 0.7% during the 2nd quarter. American Century Companies Inc. now owns 1,196,281 shares of the medical instruments supplier’s stock worth $286,581,000 after acquiring an additional 7,843 shares in the last quarter. Parsons Capital Management Inc. RI raised its holdings in shares of Becton Dickinson and by 3.5% in the 2nd quarter. Parsons Capital Management Inc. RI now owns 7,262 shares of the medical instruments supplier’s stock valued at $1,740,000 after purchasing an additional 246 shares in the last quarter. Norinchukin Bank The raised its stake in Becton Dickinson and by 2.7% during the 1st quarter. Norinchukin Bank The now owns 144,476 shares of the medical instruments supplier’s stock worth $31,308,000 after acquiring an additional 3,816 shares in the last quarter. Hudson Bay Capital Management LP raised its stake in Becton Dickinson and by 119.9% during the 2nd quarter. Hudson Bay Capital Management LP now owns 166,094 shares of the medical instruments supplier’s stock worth $39,789,000 after acquiring an additional 90,564 shares in the last quarter. Finally, FTB Advisors Inc. increased its stake in Becton Dickinson and by 231.1% in the second quarter. FTB Advisors Inc. now owns 3,784 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 2,641 shares during the period. 86.96% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE:BDX opened at $261.00 on Friday. The firm has a market cap of $68.28 billion, a price-to-earnings ratio of 27.53, a price-to-earnings-growth ratio of 1.74 and a beta of 1.10. Becton Dickinson and Co has a 1-year low of $191.53 and a 1-year high of $263.37. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.86 by $0.05. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The company had revenue of $4.28 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same quarter last year, the firm posted $2.46 EPS. The business’s revenue for the quarter was up 41.0% on a year-over-year basis. equities research analysts anticipate that Becton Dickinson and Co will post 11.01 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 28th. Investors of record on Friday, September 7th will be given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.15%. The ex-dividend date is Thursday, September 6th. Becton Dickinson and’s payout ratio is presently 31.65%.
Several equities analysts recently commented on the stock. ValuEngine lowered shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Tuesday, May 29th. JPMorgan Chase & Co. upgraded shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective for the company in a research report on Thursday, June 21st. KeyCorp reiterated a “buy” rating and issued a $264.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Royal Bank of Canada reissued a “hold” rating and issued a $248.00 price target on shares of Becton Dickinson and in a research report on Friday, August 3rd. Finally, Citigroup upped their price objective on Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a report on Wednesday, August 8th. Four equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $251.64.
Becton Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: Google Finance Portfolio
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.